BioTheryX

BioTheryX is a private, clinical-stage biopharmaceutical company headquartered in San Diego, California, discovering and developing first-in-class targeted protein degraders — both bifunctional degraders and molecular glues — for cancer and inflammatory disease. Its proprietary PRODEGY platform is built on Cereblon-binding expertise carried over from founders who worked on FDA-approved Cereblon modulators. The lead program BTX-9341, a dual CDK4/CDK6 degrader, is in Phase 1 for HR+/HER2- breast cancer, alongside BTX-10908 targeting SOS1 for pan-KRAS mutant cancers and PDE4 degraders for inflammatory conditions; the company also partners with Incyte on molecular glue degrader discovery. BioTheryX is a therapeutics developer with no public developer program: probes on 2026-08-02 returned 404 for /openapi.json, /swagger.json, /api-docs, /llms.txt and every /.well-known/ discovery path on biotheryx.com, and there is no api./developer./docs./portal. subdomain, GitHub organization, or published SDK.

BioTheryX is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.

BioTheryX’s developer surface includes engineering blog and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub
7.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesDrug DiscoveryOncologyProtein DegradationClinical TrialsHealth

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1
Composite quality — 7.3/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.9 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/biotheryx: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Biotheryx Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 6

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 BlogRSS
BlogRSS
 Careers
Careers
 LinkedIn
LinkedIn

Other 3

Properties that don't map to a standard resource type

Product
Product
 Research
Research
 Team
Team

Source (apis.yml)

apis.yml Raw ↑ 
aid: biotheryx
name: BioTheryX
description: 'BioTheryX is a private, clinical-stage biopharmaceutical company headquartered in San Diego, California, discovering
  and developing first-in-class targeted protein degraders — both bifunctional degraders and molecular glues — for cancer
  and inflammatory disease. Its proprietary PRODEGY platform is built on Cereblon-binding expertise carried over from founders
  who worked on FDA-approved Cereblon modulators. The lead program BTX-9341, a dual CDK4/CDK6 degrader, is in Phase 1 for
  HR+/HER2- breast cancer, alongside BTX-10908 targeting SOS1 for pan-KRAS mutant cancers and PDE4 degraders for inflammatory
  conditions; the company also partners with Incyte on molecular glue degrader discovery. BioTheryX is a therapeutics developer
  with no public developer program: probes on 2026-08-02 returned 404 for /openapi.json, /swagger.json, /api-docs, /llms.txt
  and every /.well-known/ discovery path on biotheryx.com, and there is no api./developer./docs./portal. subdomain, GitHub
  organization, or published SDK.'
image: https://www.biotheryx.com/wp-content/themes/biotheryx/assets/images/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/biotheryx/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-secondary-market-listing: https://forgeglobal.com/biotheryx_stock/
x-tier: stub
x-tier-reason: no-public-api-surface
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Oncology
- Protein Degradation
- Clinical Trials
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/biotheryx-domain-security.yml
- type: LLMsTxt
  url: llms/biotheryx-llms.txt
- type: Website
  url: https://www.biotheryx.com/
- type: About
  url: https://www.biotheryx.com/about-us/
- type: Product
  url: https://www.biotheryx.com/pipeline/
- type: Research
  url: https://www.biotheryx.com/our-science/
- type: Team
  url: https://www.biotheryx.com/about-us/
- type: Blog
  url: https://www.biotheryx.com/category/news/
- type: BlogRSS
  url: https://www.biotheryx.com/feed/
- type: Careers
  url: https://www.biotheryx.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/biotheryx-inc./